Intellia Therapeutics to Present at September Healthcare Investor Conferences

Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage genome editing company, will participate in two virtual healthcare investor conferences in September 2021. The first will be at the Wells Fargo Healthcare Conference on September 9 at 10:40 am ET, followed by the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 am ET. Live webcasts of the presentations will be available on Intellia's website, with replays accessible for 14 days post-event. Intellia focuses on curative therapeutics powered by CRISPR/Cas9 technology.

CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following virtual healthcare investor conferences in September:

Thursday, September 9, 2021
Wells Fargo Healthcare Conference
Time: 10:40 am ET

Monday, September 13, 2021
H.C. Wainwright 23^rd Annual Global Investment Conference
Time: 7:00 am ET

A live webcast of Intellia’s presentations at these events will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Intellia’s website for approximately 14 days following each presentation.

About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. To fully realize the transformative potential of CRISPR/Cas9, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of CRISPR/Cas9 to create new classes of genetic medicine. Learn more at intelliatx.com. Follow us on Twitter @intelliatweets.

Intellia Contacts:

Investors:
Ian Karp
Senior Vice President, Investor Relations and Corporate Communications
+1-857-449-4175
ian.karp@intelliatx.com

Lina Li
Director, Investor Relations
+1-857-706-1612
lina.li@intelliatx.com 

FAQ

What is Intellia Therapeutics presenting at the Wells Fargo Healthcare Conference?

Intellia Therapeutics will present at the Wells Fargo Healthcare Conference on September 9, 2021, at 10:40 am ET.

When is Intellia's presentation at the H.C. Wainwright 23rd Annual Global Investment Conference?

Intellia's presentation at the H.C. Wainwright 23rd Annual Global Investment Conference is scheduled for September 13, 2021, at 7:00 am ET.

How can I access Intellia Therapeutics' presentations?

You can access the live webcasts of Intellia's presentations through the Events and Presentations page on their website.

How long will the webcasts of Intellia's presentations be available after the events?

The replays of Intellia's presentations will be available for approximately 14 days after each event.

What technology does Intellia Therapeutics use for developing therapeutics?

Intellia Therapeutics utilizes CRISPR/Cas9 technology to develop potential curative therapeutics.